Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis

Sridhar Boppana; John E. Mindur; Konstantin E. Balashov; Suhayl Dhib-Jalbut; Kouichi Ito

doi:10.1016/j.jneuroim.2013.10.007

Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis

Sridhar Boppana, John E. Mindur, Konstantin E. Balashov, Suhayl Dhib-Jalbut, Kouichi Ito

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.

Original language	English (US)
Pages (from-to)	68-74
Number of pages	7
Journal	Journal of Neuroimmunology
Volume	265
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2013.10.007
State	Published - Dec 15 2013
Externally published	Yes

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Keywords

HLA-G PPMS
IFN beta inducible genes
IFN beta therapy
Multiple sclerosis
PPMS
RRMS

Access to Document

10.1016/j.jneuroim.2013.10.007

Cite this

@article{44d45f1caa144fa5bddafb0d973cc1ee,

title = "Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis",

abstract = "Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.",

keywords = "HLA-G PPMS, IFN beta inducible genes, IFN beta therapy, Multiple sclerosis, PPMS, RRMS",

author = "Sridhar Boppana and Mindur, {John E.} and Balashov, {Konstantin E.} and Suhayl Dhib-Jalbut and Kouichi Ito",

note = "Funding Information: This work was supported by EMD Serono, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany), Rockland, MA. Funding Information: Dr. Ito received financial support for research activities from Teva Pharmaceuticals and Biogen Idec. Dr. Balashov received grant support from Biogen Idec and Teva Pharmaceuticals, and consultation fees from Bayer Healthcare. Dr. Dhib-Jalbut received grant support from Teva Pharmaceuticals and EMD Serono, Inc., and consultation fees from EMD Serono, Inc. ",

year = "2013",

month = dec,

day = "15",

doi = "10.1016/j.jneuroim.2013.10.007",

language = "English (US)",

volume = "265",

pages = "68--74",

journal = "Advances in Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis

AU - Boppana, Sridhar

AU - Mindur, John E.

AU - Balashov, Konstantin E.

AU - Dhib-Jalbut, Suhayl

AU - Ito, Kouichi

N1 - Funding Information: This work was supported by EMD Serono, Inc. (an affiliate of Merck KGaA, Darmstadt, Germany), Rockland, MA. Funding Information: Dr. Ito received financial support for research activities from Teva Pharmaceuticals and Biogen Idec. Dr. Balashov received grant support from Biogen Idec and Teva Pharmaceuticals, and consultation fees from Bayer Healthcare. Dr. Dhib-Jalbut received grant support from Teva Pharmaceuticals and EMD Serono, Inc., and consultation fees from EMD Serono, Inc.

PY - 2013/12/15

Y1 - 2013/12/15

N2 - Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.

AB - Interferon (IFN)-β is a type I IFN commonly produced by the innate immune system in response to viral infection. IFN-β is also used for the treatment of patients with the relapsing-remitting form of multiple sclerosis (RRMS); however, IFN-β therapy is unable to confer a significant benefit for primary-progressive MS (PPMS) patients. In this study, we assessed the gene profiles of peripheral blood mononuclear cells (PBMCs) isolated from PPMS, RRMS, and healthy donors (HD) in response to IFN-β treatment in vitro to examine genetic mechanisms underlying the inadequate response of IFN-β therapy in PPMS patients. Here, we show that HLA-G was significantly less up-regulated in response to IFN-β in PBMCs from PPMS compared to those from RRMS. This data suggests HLA-G to be a possible candidate gene found impaired in IFN-β-mediated immune regulation in PPMS patients.

KW - HLA-G PPMS

KW - IFN beta inducible genes

KW - IFN beta therapy

KW - Multiple sclerosis

KW - PPMS

KW - RRMS

UR - http://www.scopus.com/inward/record.url?scp=84888391352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888391352&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2013.10.007

DO - 10.1016/j.jneuroim.2013.10.007

M3 - Article

C2 - 24200257

AN - SCOPUS:84888391352

SN - 0165-5728

VL - 265

SP - 68

EP - 74

JO - Advances in Neuroimmunology

JF - Advances in Neuroimmunology

IS - 1-2

ER -

Comparison of IFN-β inducible gene expression in primary-progressive and relapsing-remitting multiple sclerosis

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Access to Document

Other files and links

Fingerprint

Cite this